司太立(603520.SH):減持期滿 控股股東之一致人完成減持2.16%股份
格隆匯7月12日丨司太立(603520.SH)發佈控股股東之一致行動人減持股份結果公吿,本減持計劃實施期間,胡愛敏於2021年2月5日至2021年3月18日,通過集中競價交易、大宗交易方式合計減持公司股份529.2萬股,佔公司總股本的2.16%;股東胡健未減持公司股份。截至本公吿披露日,本次減持計劃時間已屆滿。
據悉,胡健、胡愛敏與公司控股股東胡錦生為一致行動人關係,合計持有公司股份9437.4萬股,佔公司總股本的38.54%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.